Exosome Technologies Global Market Report 2024

Two primary types of exosome technologies are loaded cargo and non-cargo. Loaded cargo pertains to exosomes that have been modified to carry specific cargos, including therapeutic agents, employing passive or active loading methods. These engineered exosomes are derived from various cell sources such as HEK293 cells, mesenchymal stem cells (MSCs), platelets, erythrocytes, natural killer cells, and others. They find applications in both therapeutics and diagnostics, with end-users encompassing healthcare providers, pharmaceutical and biotechnology companies, and other entities.

The exosome technologies market research report provides exosome technologies market statistics, including exosome technologies industry global market size, regional shares, competitors with an exosome technologies market share, detailed exosome technologies market segments, market trends and opportunities, and any further data you may need to thrive in the exosome technologies industry. This exosome technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The exosome technologies market has grown exponentially in recent years. It will grow from $0.06 billion in 2023 to $0.07 billion in 2024 at a compound annual growth rate (CAGR) of 26.7%. The expansion observed in the historical period can be credited to progress in therapeutics, advancements in isolation techniques, increased funding for research, exploration of regenerative medicine, and the initiation of clinical trials.

The exosome technologies market is expected to see exponential growth in the next few years. It will grow to " $0.18 billion in 2028 at a compound annual growth rate (CAGR) of 27.0%.
The anticipated growth in the forecast period can be ascribed to advancements in regulatory frameworks, innovations in biomedical engineering, proliferation of clinical trials, development in regenerative medicine, and the growth of nanotechnology integration. Major trends expected in the forecast period include advancements in therapeutics, applications in diagnostics, integration of nanotechnology, a surge in research funding, and the development of isolation techniques.

The anticipated growth in the exosome technologies market is driven by the increasing prevalence of chronic diseases. Chronic diseases, characterized by persistent or long-lasting effects lasting three months or more, are on the rise, creating a demand for exosome technologies. These technologies play a crucial role in identifying disease-specific biomarkers, monitoring disease progression through exosome cargo analysis, facilitating targeted drug delivery, and immune modulation in chronic conditions. For instance, statistics from January 2023 indicate that the number of individuals aged 50 years and older with one or more chronic illnesses in the United States is projected to increase by 99.5%, reaching 142.66 million by 2050, up from 71.522 million in 2020. In Australia, an estimated 47% of the population, or 11.6 million individuals, are affected by at least one of the ten selected chronic ailments, as reported by the Australian Institute of Health and Welfare (AIHW) in July 2022. Hence, the escalating prevalence of chronic diseases is expected to drive the growth of the exosome technologies market.

The upward trajectory of healthcare expenditure is poised to propel the exosome technologies market. Healthcare expenditure, encompassing the total financial outlay on healthcare services, goods, and activities within a specific healthcare system or economy over a defined period, serves as a pivotal factor in advancing exosome technologies. This financial support fuels research and development initiatives, facilitates reimbursement for clinical applications, promotes the market for chronic disease management, and supports infrastructure development. Notably, in the UK, healthcare spending experienced a 9.4% increase in nominal terms and a 9.7% rise in real terms between 2020 and 2021. The total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion) in 2021, with pharmaceutical expenditure standing at $51.84 billion (£39.6 billion). Moreover, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from 2020. Thus, the escalating healthcare expenditures contribute to the growth of the exosome technologies market.

The exosome technology market is witnessing a prominent trend in the adoption of advanced exosome characterization technologies. Companies within this market are integrating new technologies to maintain their competitive standing. For example, in August 2022, Creative Biolabs Inc., a biotech company based in the United States, introduced the NanosightTM platform for exosome characterization, leveraging Nanosight technology. Nanosight is a nanoparticle tracking analysis (NTA) technique enabling the visualization and quantification of exosomes based on their size and concentration. By offering this platform, Creative Biolabs intends to equip researchers with sophisticated tools for the comprehensive characterization and analysis of exosomes, facilitating a deeper understanding of their properties and functions.

Major players in the exosome technology sector are embracing a strategic partnership approach, seeking to capitalize on synergies and expedite progress in this dynamically evolving field. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutually beneficial outcomes. In June 2023, RoosterBio Inc., a biotechnology firm based in the United States, forged a partnership with Repligen, a life sciences company focused on bioprocessing. This collaboration aims to accelerate the development of scalable and cost-effective exosome bioprocessing solutions, ultimately enhancing accessibility to exosome-based therapies for patients.

In November 2021, Lonza, a Switzerland-based biotechnology research company, completed the acquisition of Codiak BioSciences' exosome manufacturing facility for $65 million. This strategic move by Lonza is geared toward fortifying its presence in the exosome market and meeting the escalating demand for exosome-based therapeutics and diagnostics. Codiak BioSciences, a U.S.-based biopharmaceutical company, specializes in the development of exosome-based therapeutics.

Major companies operating in the exosome technologies market report are AEGLE Therapeutics, Aruna Bio Inc., Carmine Therapeutics Inc., Exosome Diagnostics Inc., Creative Biolabs Inc., Danaher Corporation, OmniSpirant Limited, Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, Anjarium Biosciences, NOVADIP Biosciences S.A., Exopharm Ltd., Organicell Regenerative Medicine Inc., Evox Therapeutics, Direct Biologics, ExoCan Healthcare Technologies Pvt. Ltd., ExoCoBio, ExonanoRNA LLC, ILIAS Biologics Inc., Illumina Inc., Invitrix Therapeutics, XOStem Inc., VivaZome Therapeutics Pty Ltd., Aethlon Medical Inc., Capricor Therapeutics, Codiak BioSciences, Exogenus Therapeutics, Exovita Biosciences, HansaBioMed Life Sciences, Hitachi Chemical Advanced Therapeutics Solutions.

North America was the largest region in the exosome technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global exosome technologies market report during the forecast period. The regions covered in the exosome technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the exosome technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exosome technologies market consists of revenues earned by entities by providing exosome technologies services such as vaccine development, biomarker production, exosome-based diagnostic testing, and therapeutic development. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. The exosome technologies market consists of sales of exosome isolation kits, purification reagents, characterization tools, analysis kits, and exosome-based therapeutic products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.